Department of Research, California North-state University College of Medicine , Elk Grove, CA, USA.
Department of Clinical Sciences, UT Southwestern Medical Center , Dallas, TX, USA.
Endocr Res. 2020 Nov;45(4):241-245. doi: 10.1080/07435800.2020.1811724. Epub 2020 Aug 24.
Metabolic Syndrome (MetS) a global problem, which comprises a cardio-metabolic cluster of risk factors, increases the risk for type-2 diabetes (T2DM) and atherosclerotic cardiovascular diseases (ASCVD). To date, the best laboratory-based biomarker for MetS appears to be high-sensitivity C-reactive protein (hsCRP). Chemerin, a novel adipokine is increased in MetS and appears to contribute to both insulin resistance and inflammation. In this pilot study, we tested if the chemerin:HDL-C or chemerin:adiponectin ratios are better biomarkers for predicting MetS than hsCRP.
We enrolled patients and controls with nascent MetS, uncomplicated by diabetes, ASCVD, macro-inflammation, and smoking using rigorous criteria. Fasting blood samples were obtained in order to calculate insulin resistance in the liver (HOMA-IR) and adipose tissue (ADIPO-IR) and for measurement of chemerin and adiponectin levels. Statistical analyses including receiver operating characteristic (ROC) curves were used to evaluate data.
We observed the chemerin:HDL-C ratio is significantly increased in MetS and increases with severity of MetS ( < .001). The chemerin: adiponectin ratio was not significantly increased following adjustment for age and waist circumference. The chemerin:HDL-C ratio correlated with BMI, WC, triglycerides, plasma glucose, HDL-C, and both HOMA-IR and ADIPO-IR. ROC curve analysis showed that the chemerin:HDL-C ratio area under the curve (AUC) was greater than the AUC for hsCRP.
In this preliminary report, we demonstrate that the ratio of chemerin to HDL-C is a valid biomarker of MetS and appears to be a better predictor than hsCRP. These findings need to be confirmed in larger studies.
代谢综合征（MetS）是一个全球性问题，它包含一组心血管代谢危险因素，增加了 2 型糖尿病（T2DM）和动脉粥样硬化性心血管疾病（ASCVD）的风险。迄今为止，用于 MetS 的最佳实验室生物标志物似乎是高敏 C 反应蛋白（hsCRP）。Chemerin 是一种新型脂肪因子，在 MetS 中增加，似乎有助于胰岛素抵抗和炎症。在这项初步研究中，我们测试了 chemerin：HDL-C 或 chemerin：脂联素比值是否比 hsCRP 更能预测 MetS。
我们使用严格的标准招募了患有新生代谢综合征的患者和对照者，这些患者没有糖尿病、ASCVD、巨细胞炎症和吸烟。采集空腹血样以计算肝脏（HOMA-IR）和脂肪组织（ADIPO-IR）的胰岛素抵抗，并测量 chemerin 和脂联素水平。使用包括接收者操作特征（ROC）曲线在内的统计分析来评估数据。
我们观察到 chemerin：HDL-C 比值在 MetS 中显著增加，并随 MetS 的严重程度增加而增加（<0.001）。在调整年龄和腰围后，chemerin：脂联素比值没有显著增加。chemerin：HDL-C 比值与 BMI、WC、甘油三酯、血浆葡萄糖、HDL-C 以及 HOMA-IR 和 ADIPO-IR 均相关。ROC 曲线分析显示，chemerin：HDL-C 比值曲线下面积（AUC）大于 hsCRP 的 AUC。
在这项初步报告中，我们证明了 chemerin 与 HDL-C 的比值是 MetS 的有效生物标志物，似乎比 hsCRP 更能预测。这些发现需要在更大的研究中得到证实。
